Data will be presented on Monday, November 18th as a late breaker poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 in San Diego.LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo.50% percent of patients saw their HbA1c levels below 6.5% at week 24 following treatment with lanifibranor alone or in combination with empagliflozin. 58% ...

The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data. The recommendation was based on the unblinded review by the DMC of safety data from more than 1000 patients randomized in the main and exploratory cohorts, including over 800 and 170 patients that have been treated for more than 24 and 72 weeks, respectively. This fifth DMC review confirms the good safety profile of lanifibranor. Daix (France) ...

Daix (France), Long Island City (New York, United States), October 21, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), today announced that the results of the Phase 2, LEGEND, evaluating lanifibranor in combination with empagl ...

Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH") and other diseases with significant unmet medical needs, today announces that the Autorité des marchés financiers (the "AMF") has approved a prospectus under no. 24-432, on Octo ...

文章核心观点 - 公司发布了2024年上半年报告 [1] - 公司的财务信息未被审计师限定 [2] - 公司主要从事代谢紊乱相关脂肪肝(MASH/NASH)和其他疾病的口服小分子治疗药物的研发 [3] 公司概况 - 公司拥有约90人的科学团队,在生物学、药物化学、药代动力学和药理学、临床开发等领域具有深厚专业知识 [4] - 公司拥有约24万个药理学相关分子的广泛化合物库,其中约60%为自有 [4] - 公司在法国和美国上市,股票代码分别为IVA [5] 产品管线 - 公司的领先候选药物lanifibranor正处于III期临床试验阶段,用于治疗成人MASH/NASH患者 [3] - 公司的另一候选药物odiparcil用于治疗成人粘多糖贮积症VI型患者,公司暂停了相关临床试验并正在评估进一步开发的选择 [4] - 公司正在选择一个用于调节Hippo信号通路的候选药物 [4]

文章核心观点 - 公司宣布完成总额最高达3.48亿欧元的多轮次股权融资 [1][2][3] - 融资所得将主要用于推进公司的NASH III期临床试验 [9] - 公司已有超过1100名患者参与NASH III期临床试验 [1] - 公司任命Mark Pruzanski博士为董事长,Srinivas Akkaraju博士为董事 [1][3][25][26] 根据目录分别进行总结 融资交易概况 - 公司完成总额最高达3.48亿欧元的多轮次股权融资 [1][2][3][6] - 首轮融资94.1百万欧元,后续还有21.4百万欧元和116百万欧元两轮融资 [6][10] - 融资由多家新老投资者参与,包括NEA、BVF、Samsara BioCapital等 [3] - 融资所得将主要用于推进NASH III期临床试验和准备上市申请 [9][10][11] 临床试验进展 - 公司已有超过1100名患者参与NASH III期临床试验,预计2025年上半年完成入组 [1] - 公司还计划启动NASH合并肝硬化患者的III期临床试验 [10] 公司治理变动 - 公司任命Mark Pruzanski博士为董事长,Srinivas Akkaraju博士为董事 [1][3][25][26] - 未来还将增加4名新董事,由其他4大投资者提名,其中至少2名独立董事 [3][25][26] - 董事长和CEO职务将分离,Frederic Cren将担任CEO [27] 里程碑付款 - 如果公司在2024年12月31日前完成至少1.8亿欧元的股权融资,合作伙伴CTTQ将支付公司1000万美元里程碑付款 [8] - 后续还有两笔1000万美元的里程碑付款 [8] 财务状况 - 公司目前现金和现金等价物不足以满足未来12个月的义务 [12][13][15] - 本次融资后,公司现金流可延长至2025年第二季度 [15] - 如果后续融资未能完成,公司还需要筹集4000万欧元以满足未来12个月的义务 [15][16]

A downtrend has been apparent in Inventiva S.A. Sponsored ADR (IVA) lately with too much selling pressure. The stock has declined 17.7% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical ...

Recruitment in NATiV3 clinical trial progresses with over 85% of the targeted number of patients enrolled in the main cohort and a statistical powering of the study expected to be superior to 95% for both doses evaluated in the trial. Baseline characteristics of patients randomized in the main cohort of NATiV3 remain consistent with the characteristics of patients enrolled in the completed Phase IIb, NATIVE, clinical trial. Blinded analyses of patients in NATiV3 suggest a positive evolution of key biomarker ...

Daix (France), Long Island City (New York, United States), July 19, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity ...

Royalty certificates subscribed by Samsara BioCapital and existing shareholders (BVF Partners, NEA, Sofinnova and Yiheng).Royalty of 3% on future net sales of lanifibranor in the United States of America, the European Union and the United Kingdom over a 14-year term.Cash runway extended through September 2024 and evaluation of strategic and financing options pursued1. Daix (France), Long Island City (New York, United States), July 18, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Co ...